Table 2.
Reported routine and investigational indications in faecal microbiota transplantation (FMT) in Europe, 2019.
| Indication | n* | % |
|---|---|---|
| Routine clinical indications. (n = 30 centres) | ||
| Clostridioides difficile infection (CDI): | ||
| Recurrent CDI | 30 | 100% |
| Antibiotic refractory CDI | 27 | 90% |
| Critical CDI | 14 | 47% |
| Experimental (outside trials) indications. (n = 30 centres) | ||
| Ulcerative colitis | 4 | 13% |
| Multidrug resistant organisms carriage | 3 | 10% |
| Graft versus host disease | 2 | 7% |
| Irritable bowel syndrome | 1 | 3% |
| Pouchitis | 1 | 3% |
| Antibiotic-associated diarrhoea, not CDI. | 1 | 3% |
| Investigational (within trials) indications. (n = 24 centres) | ||
| Ulcerative colitis | 11 | 46% |
| Irritable bowel syndrome | 7 | 30% |
| Multidrug resistant organisms carriage | 5 | 21% |
| Recurrent CDI | 3 | 13% |
| Index CDI | 3 | 13% |
| Refractory CDI | 2 | 8% |
| Crohn's disease | 2 | 8% |
| Pouchitis | 2 | 8% |
| Graft versus host disease | 2 | 8% |
| Obesity | 2 | 8% |
| Spondyloarthropathy | 2 | 8% |
| Liver cirrhosis, hepatic encephalopathy | 2 | 8% |
| Critical CDI | 1 | 4% |
| Antibiotic-associated diarrhoea, not CDI | 1 | 4% |
| Parkinson's disease | 1 | 4% |
| Chemotherapy-related diarrhoea | 1 | 4% |
| Non-alcoholic fatty liver disease (NAFLD) | 1 | 4% |
| Chronic fatigue syndrome | 1 | 4% |
| Microscopic colitis | 1 | 4% |
⁎
1 unanswered response in total.
Abbreviations: CDI: Clostridioides difficile infection, NAFLD: Non-alcoholic fatty liver disease.